CN105288243A - Traditional Chinese medicine for curing cerebral infarction, cerebral palsy, cerebral atrophy, thoracic obstruction, coronary disease and stenocardia - Google Patents
Traditional Chinese medicine for curing cerebral infarction, cerebral palsy, cerebral atrophy, thoracic obstruction, coronary disease and stenocardia Download PDFInfo
- Publication number
- CN105288243A CN105288243A CN201510856875.6A CN201510856875A CN105288243A CN 105288243 A CN105288243 A CN 105288243A CN 201510856875 A CN201510856875 A CN 201510856875A CN 105288243 A CN105288243 A CN 105288243A
- Authority
- CN
- China
- Prior art keywords
- parts
- cerebral
- radix
- thoracic obstruction
- chinese medicine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Abstract
The invention relates to a traditional Chinese medicine for curing cerebral infarction, cerebral palsy, cerebral atrophy, thoracic obstruction, coronary disease and stenocardia. The traditional Chinese medicine is prepared from the following substances in parts by weight: 12 parts of notopterygium root, 12 parts of Radix Saposhnikoviae, 18 parts of radices ligustici sinensis, 18 parts of gypsum, 18 parts of rhizoma cyperi, 18 parts of the rhizome of chuanxiong, 18 parts of Radix angelicae dahurioae, 15 parts of asarum, 15 parts of gastrodia elata, 18 parts of chaste tree fruit, 6 parts of buthus martensi karsch, 20 parts of centipede, 18 parts of safflower carthamus, 9 parts of pseudo-ginseng, 30 parts of lotus leaf, 30 parts of root of common peony, 30 parts of the root of red-rooted salvia, 18 parts of radix scrophulariae, 12 parts of leech, 18 parts of aloe, 18 parts of indigo naturalis, 20 parts of caulis perllae, 18 parts of semen brassicae, 16 parts of immature bitter orange, 15 parts of cassia twig and 25 parts of snake gourd seed. The traditional Chinese medicine composition provided by the invention has the indications and functions of clearing yang and dredging collaterals, and promoting blood circulation to remove blood stasis, and is used for the symptoms of lucid yang failing to rise, headache pathopoiesia, light-headedness, bitter mouth and dry throat, astriction of patients with stroke and collaterals activating, stiff tongue and difficult speak, hemiplegia, facial paralysis, thoracic obstruction and chest distress, palpitation and chest pain, lacunar infarction, coronary disease and stenocardia.
Description
Technical field
The present invention relates to field of medicaments, relate in particular to a kind of Chinese drugs agentia for the treatment of cerebral infarction, cerebral palsy, brain atrophy, the thoracic obstruction, coronary heart diseases and angina pectoris.
Background technology
Angina pectoris is one of the commonly encountered diseases, frequently-occurring disease of clinical cardiovascular aspect, angina pectoris belongs to the category of the traditional Chinese medical science " thoracic obstruction " " angina pectoris ", for common clinical, frequently-occurring disease, especially unstable angina pectoris, it is the clinical state between stable angina pectoris and acute myocardial infarction, it includes first hair style, deterioration type effort angina and various spontaneous angina pectoris except stable effort angina, is the common type of acute coronary syndrome.Its state of an illness weight, the oncoming force is anxious, and change is fast, sudden death rate is high, extremely easily develops into acute myocardial infarction, prognosis mala, therefore control anginal outbreak well, the improvement that alleviating clinical symptoms becomes on its main orientation treatment treatment treating coronary heart disease and angina pectoris is the problem needing solution at present badly.
Summary of the invention
The object of this invention is to provide a kind of Chinese drugs agentia for the treatment of cerebral infarction, cerebral palsy, brain atrophy, the thoracic obstruction, coronary heart diseases and angina pectoris.
In order to realize object of the present invention, the invention provides one and treat cerebral infarction, cerebral palsy, brain atrophy, the thoracic obstruction, coronary heart disease, anginal Chinese drugs agentia, it comprises the material of following weight portion: Rhizoma Et Radix Notopterygii 12 parts, Radix Saposhnikoviae 12 parts, Rhizoma Ligustici 18 parts, 18 parts, Gypsum Fibrosum, Rhizoma Cyperi 18 parts, Rhizoma Chuanxiong 18 parts, the Radix Angelicae Dahuricae 18 parts, Herba Asari 15 parts, 15 parts, Rhizoma Gastrodiae, Fructus Viticis 18 parts, Scorpio 6 parts, Scolopendra 20 parts, 18 parts, Flos Carthami, Radix Notoginseng 9 parts, 30 parts, Folium Nelumbinis, Radix Paeoniae Rubra 30 parts, Radix Salviae Miltiorrhizae 30 parts, Radix Scrophulariae 18 parts, Hirudo 12 parts, Aloe 18 parts, Indigo Naturalis 18 parts, Caulis Perillae 20 parts, Semen Sinapis Albae 18 parts, Fructus Aurantii Immaturus 16 parts, Ramulus Cinnamomi 15 parts and Semen Trichosanthis 25 parts.
Preferably; the Chinese drugs agentia for the treatment of cerebral infarction of the present invention, cerebral palsy, brain atrophy, the thoracic obstruction, coronary heart diseases and angina pectoris also comprises the material of following weight portion: the 6-(3-(2 of 0.01 part; 4-Dimethoxyphenyl) acryloyl group-2H-benzo [b] [Isosorbide-5-Nitrae] oxazine-3 (4H)-one.
More preferably, described Chinese medicine composition can be tablet, dispersible tablet, capsule, pill or decoction.
The present invention also provides 6-(3-(2; 4-Dimethoxyphenyl) acryloyl group-2H-benzo [the b] [purposes of Isosorbide-5-Nitrae] oxazine-3 (4H)-one in the medicine of preparation treatment cerebral infarction, cerebral palsy, brain atrophy, the thoracic obstruction, coronary heart diseases and angina pectoris.
Preferably, described medicine can be tablet, dispersible tablet, capsule, pill or decoction.
The function of Chinese medicine composition of the present invention cures mainly: clear positive dredging collateral, blood circulation promoting and blood stasis dispelling.For hypofunction of clear YANG, sincere disease of having a headache, have a dizzy spell, bitter taste in the mouth and dry throat, constipation, to active in wind, stiff tongue speech not smoothgoing, hemiplegia, facial hemiparalysis, the thoracic obstruction is uncomfortable in chest, cardiopalmus chest pain, chamber temperament cerebral infarction, coronary heart disease, the above-mentioned symptom of angina pectoris patient.
Detailed description of the invention
The present invention is further illustrated below by embodiment.It should be understood that embodiments of the invention are for illustration of the present invention instead of limitation of the present invention.Essence according to the present invention all belongs to the scope of protection of present invention to the simple modifications that the present invention carries out.Unless otherwise stated, the percent in the present invention is percetage by weight.
Embodiment
Take Rhizoma Et Radix Notopterygii 12 grams, Radix Saposhnikoviae 12 grams, Rhizoma Ligustici 18 grams, 18 grams, Gypsum Fibrosum, Rhizoma Cyperi 18 grams, Rhizoma Chuanxiong 18 grams, the Radix Angelicae Dahuricae 18 grams, Herba Asari 15 grams, 15 grams, Rhizoma Gastrodiae, Fructus Viticis 18 grams, Scorpio 6 grams, Scolopendra 20 grams, 18 grams, Flos Carthami, Radix Notoginseng 9 grams, 30 grams, Folium Nelumbinis, Radix Paeoniae Rubra 30 grams, Radix Salviae Miltiorrhizae 30 grams, Radix Scrophulariae 18 grams, Hirudo 12 grams, Aloe 18 grams, Indigo Naturalis 18 grams, Caulis Perillae 20 grams, Semen Sinapis Albae 18 grams, Fructus Aurantii Immaturus 16 grams, Ramulus Cinnamomi 15 grams and Semen Trichosanthis 25 grams, pulverize, cross 100 mesh sieves, mix homogeneously obtains powder.
Experimental example
Thrombosis suspension makes
Get SD rat of the same race 10,280-300g, male and female half and half, under aseptic condition, taken a blood sample by vena ophthalmica clump, natural drying, become blood clot, through 180 μm of sieve sieving for standby after grinding with mortar, add blood clot with normal saline during application and make 200mg/mL thrombosis suspension.Measure its diameter under microscope, find that embolus diameter is at 40-180 μm, in the majority with 130-180 μm.
The making of cerebral infarction model rat
Get SD rat of the same race 120,280-300g, male and female half and half, the anaesthetized with pentobarbital (1mL/100g) with 3%, after anesthesia, lies on the back rat and is fixed on flat board.Neck medisection exposes left common carotid artery, isolate in neck, external carotid artery, temporarily press from both sides with metal bulldog clamp and close common carotid artery, after left neck dynamic outer arteries and veins place retrograde catheterization injects thrombosis salt aqueous suspension 0.5mL, ligation external carotid artery immediately, simultaneously open common carotid artery, embolus is made to enter rapidly intracranial to each tremulous pulse of brain by ICAF, cause multifocal cerebral infarction, all operation techniques of sham operated rats with modeling group, but only inject the normal saline not containing embolus of equivalent in neck.
Post surgery treatment
Postoperative wound is sewed up, and is coated with iodine tincture, and uses penicillin antiinflammatory, is then raised by single for rat cage.
Neuroethology is observed
Post operation carries out neuroethology observation in second day, and carries out neuroethology classification: normal (0 grade), has no movable abnormal; Slightly (I level), can walk, but take on after-applied side direction motive force Mus Mus is slided about 10-15cm, feel paralysis collateral resistance reduces; Moderate (II level), can walk, but occur pitch of the laps phenomenon; Severe (III level), can stand, but difficulty of walking.Observe the neuroethology change of animal, the classification of modeling rat behavioristics all reaches more than I level and shows modeling success.Result shows, the neurobehavioral histological grading of modeling rat all reaches more than I level, shows modeling success; And sham operated rats is 0 grade.
Rat is carried out random packet by neurobehavioral histological grading, is divided into 6 groups: sham operated rats, model group, positive drug group, administration group 1, administration group 2 and administration group 3.Positive drug group: gavage piracetam solution (0.4g/kg); Administration group 1, the powder 10g of embodiment adds 1000mL normal saline and becomes suspension, gives gavage 1mL/100g body weight; ([Isosorbide-5-Nitrae] oxazine-3 (4H)-one adds 1000mL normal saline and becomes suspension 3-(2,4-Dimethoxyphenyl) acryloyl group-2H-benzo [b] 6-of administration group 2,0.01g, gives gavage 1mL/100g body weight; Administration group 3; 6-(the 3-(2 of powder 5g and 0.005g of embodiment; 4-Dimethoxyphenyl) [Isosorbide-5-Nitrae] oxazine-3 (4H)-one adds 1000mL normal saline and becomes suspension acryloyl group-2H-benzo [b], gives gavage 1mL/100g body weight.Model group, sham operated rats such as to gavage at the capacity distilled water, 1mL/100g body weight.Every day is administered once, continuous 3 weeks.
Recall tests
The learning and memory of rat was tested with MG-2 labyrinth (production of Biomedical Instruments factory of Zhangjagang City) respectively at after administration 10 days.During training, rat is put into after I arm starting area stops 3min and shock by electricity (35V), by I-II-III-I or I-III-II-I long run test.A item: mice arrives place of safety and stops 0.5min, then takes out and puts back to former arm, give after 1min next time electric shock, reach continuous 2 times and directly escape to place of safety, using escape into place of safety to carry out electric shock as starting area and train.Directly escape to place of safety when rat all reaches continuous 2 times at III arm, carry out the test of b item: rat is shocked by electricity after I arm starting area stops 1min, escape to stop 0.5min to place of safety, Zai Yici district shocks by electricity as starting area, continuous circulation electric shock training (between every twice electric shock rest 1min), remember index using continuous 10 (or 9/10) correct responses (directly escaping into place of safety) of rat as spatial discrimination, the electric shock total degree often returning successive learning is generally no more than 30 times.Finally a item and b item are added as training achievement, statistical learning achievement.School grade sees the following form.
| Group | N (only) | Test result (number of times) |
| Sham operated rats | 20 | 30.61±6.38 |
| Model group | 20 | 49.27±8.32 |
| Positive drug group | 20 | 32.65±6.13 |
| Administration group 1 | 20 | 37.28±6.28 |
| Administration group 2 | 20 | 33.26±5.21 |
| Administration group 3 | 20 | 35.18±6.33 |
After 10 days, the effect of all administration groups with the effect of positive drug group closely.
Claims (5)
1. a treatment cerebral infarction, cerebral palsy, brain atrophy, the thoracic obstruction, coronary heart disease, anginal Chinese drugs agentia, it is characterized in that, it comprises the material of following weight portion: Rhizoma Et Radix Notopterygii 12 parts, Radix Saposhnikoviae 12 parts, Rhizoma Ligustici 18 parts, 18 parts, Gypsum Fibrosum, Rhizoma Cyperi 18 parts, Rhizoma Chuanxiong 18 parts, the Radix Angelicae Dahuricae 18 parts, Herba Asari 15 parts, 15 parts, Rhizoma Gastrodiae, Fructus Viticis 18 parts, Scorpio 6 parts, Scolopendra 20 parts, 18 parts, Flos Carthami, Radix Notoginseng 9 parts, 30 parts, Folium Nelumbinis, Radix Paeoniae Rubra 30 parts, Radix Salviae Miltiorrhizae 30 parts, Radix Scrophulariae 18 parts, Hirudo 12 parts, Aloe 18 parts, Indigo Naturalis 18 parts, Caulis Perillae 20 parts, Semen Sinapis Albae 18 parts, Fructus Aurantii Immaturus 16 parts, Ramulus Cinnamomi 15 parts and Semen Trichosanthis 25 parts.
2. the Chinese drugs agentia for the treatment of cerebral infarction according to claim 1, cerebral palsy, brain atrophy, the thoracic obstruction, coronary heart diseases and angina pectoris; it is characterized in that; it also comprises the material of following weight portion: the 6-(3-(2 of 0.01 part; 4-Dimethoxyphenyl) acryloyl group-2H-benzo [b] [Isosorbide-5-Nitrae] oxazine-3 (4H)-one.
3. the Chinese drugs agentia for the treatment of cerebral infarction according to claim 1 and 2, cerebral palsy, brain atrophy, the thoracic obstruction, coronary heart diseases and angina pectoris, is characterized in that, described Chinese medicine composition can be tablet, dispersible tablet, capsule, pill or decoction.
4.6-(3-(2; 4-Dimethoxyphenyl) acryloyl group-2H-benzo [the b] [purposes of Isosorbide-5-Nitrae] oxazine-3 (4H)-one in the medicine of preparation treatment cerebral infarction, cerebral palsy, brain atrophy, the thoracic obstruction, coronary heart diseases and angina pectoris.
5. purposes according to claim 4, is characterized in that, described medicine can be tablet, dispersible tablet, capsule, pill or decoction.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510856875.6A CN105288243A (en) | 2015-11-29 | 2015-11-29 | Traditional Chinese medicine for curing cerebral infarction, cerebral palsy, cerebral atrophy, thoracic obstruction, coronary disease and stenocardia |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510856875.6A CN105288243A (en) | 2015-11-29 | 2015-11-29 | Traditional Chinese medicine for curing cerebral infarction, cerebral palsy, cerebral atrophy, thoracic obstruction, coronary disease and stenocardia |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN105288243A true CN105288243A (en) | 2016-02-03 |
Family
ID=55186521
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201510856875.6A Pending CN105288243A (en) | 2015-11-29 | 2015-11-29 | Traditional Chinese medicine for curing cerebral infarction, cerebral palsy, cerebral atrophy, thoracic obstruction, coronary disease and stenocardia |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN105288243A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107556313A (en) * | 2017-10-07 | 2018-01-09 | 扬州大学附属医院 | A kind of active component for being isolated from the red sage root and its application in cranial vascular disease is treated |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20110018671A (en) * | 2009-08-18 | 2011-02-24 | 경희대학교 산학협력단 | Pharmaceutical compositions for prevention and treatment of cardiovascular disease caused by hypercholesterinemia containing fruits cornus kousa burg. extracts, fractions, the isolated triterpene compounds therefrom, or the pharmaceutically acceptable salts as an active ingredient |
| CN103417851A (en) * | 2012-05-22 | 2013-12-04 | 赵成喜 | Traditional Chinese medicine capable of clearing and activating the channels and collaterals and promoting blood circulation to remove blood stasis |
| CN103656047A (en) * | 2013-12-19 | 2014-03-26 | 贵州景峰注射剂有限公司 | Lemai pill composition with high paeoniflorin content |
| CN103755659A (en) * | 2014-02-25 | 2014-04-30 | 山东大学 | 6-cinnamon acyl-2H-benzo [b] [1, 4] oxazine-3 (4H)-ketone compound and application thereof |
| CN104587181A (en) * | 2015-02-05 | 2015-05-06 | 王显勇 | Traditional Chinese medicine composition for treating coronary heart disease |
-
2015
- 2015-11-29 CN CN201510856875.6A patent/CN105288243A/en active Pending
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20110018671A (en) * | 2009-08-18 | 2011-02-24 | 경희대학교 산학협력단 | Pharmaceutical compositions for prevention and treatment of cardiovascular disease caused by hypercholesterinemia containing fruits cornus kousa burg. extracts, fractions, the isolated triterpene compounds therefrom, or the pharmaceutically acceptable salts as an active ingredient |
| CN103417851A (en) * | 2012-05-22 | 2013-12-04 | 赵成喜 | Traditional Chinese medicine capable of clearing and activating the channels and collaterals and promoting blood circulation to remove blood stasis |
| CN103656047A (en) * | 2013-12-19 | 2014-03-26 | 贵州景峰注射剂有限公司 | Lemai pill composition with high paeoniflorin content |
| CN103755659A (en) * | 2014-02-25 | 2014-04-30 | 山东大学 | 6-cinnamon acyl-2H-benzo [b] [1, 4] oxazine-3 (4H)-ketone compound and application thereof |
| CN104587181A (en) * | 2015-02-05 | 2015-05-06 | 王显勇 | Traditional Chinese medicine composition for treating coronary heart disease |
Non-Patent Citations (5)
| Title |
|---|
| 万秀英等: "息风解痉活血通络法治疗不稳定型心绞痛", 《中西医结合心脑血管病杂志》 * |
| 孙启时: "《药用植物学》", 30 September 2009, 中国医药科技出版社 * |
| 胡本祥等: "《生药学》", 30 September 2013, 西安交通大学出版社 * |
| 陈光福: "《儿科临床诊断学》", 30 June 2002, 天津科学技术出版社 * |
| 马永琦: "《心脑病从痰瘀论治》", 30 September 2014, 人民军医出版社 * |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107556313A (en) * | 2017-10-07 | 2018-01-09 | 扬州大学附属医院 | A kind of active component for being isolated from the red sage root and its application in cranial vascular disease is treated |
| CN107556313B (en) * | 2017-10-07 | 2019-11-01 | 扬州大学附属医院 | A kind of active constituent being isolated from Radix Salviae Miltiorrhizae and its application in treatment cranial vascular disease |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN104940796A (en) | Traditional Chinese medicine composition for promoting blood circulation to remove blood stasis and relieving swelling and pain | |
| CN102772748B (en) | Traditional Chinese medicine preparation for treating liver-depression qi-stagnation type viral myocarditis and preparation method thereof | |
| CN104306514A (en) | Traditional Chinese medicine spray and preparation method thereof | |
| CN104587181A (en) | Traditional Chinese medicine composition for treating coronary heart disease | |
| CN101745078A (en) | Chinese medicinal composition for treating cardiac failure and preparation method thereof | |
| CN106668274A (en) | External traditional Chinese medicinal healthcare preparation with effects of beautifying features, relieving pain and relieving itching and preparation method thereof | |
| CN104940810A (en) | Traditional Chinese medicine composition for treating angina | |
| CN108785422A (en) | A kind of Chinese medicine composition and preparation method thereof for treating acute mastitis | |
| CN104258292A (en) | Drug for department of obstetrics and gynecology for treating pregnancy complication and manufacturing method thereof | |
| CN104524178A (en) | Traditional Chinese medicine composition for treating facial paralysis | |
| CN105327036A (en) | Traditional Chinese medicine preparation for treating senile dementia, encephalatrophy and dysgnosia | |
| CN105288243A (en) | Traditional Chinese medicine for curing cerebral infarction, cerebral palsy, cerebral atrophy, thoracic obstruction, coronary disease and stenocardia | |
| CN103356952A (en) | Chinese medicine composition for treating arrhythmia | |
| CN101912540A (en) | Medicament for treating cerebral infarction | |
| CN104587398A (en) | Microorganism fermented traditional Chinese medicinal preparation as well as preparation method and application thereof | |
| CN106310179A (en) | Application of traditional Chinese medicine composition in preparing medicine for treating acute and chronic gastroenteritis | |
| CN103083559A (en) | Novel preparation method and application of traditional Chinese medicine composition for treating cerebral infarction during acute stage and earlier restoration stage | |
| CN105663299A (en) | Traditional Chinese medicine preparation for treating stable angina pectoris and preparing method of traditional Chinese medicine preparation | |
| CN105456924A (en) | Traditional Chinese medicine preparation containing Folium Artemisiae Argyi and having functions of promoting circulation and removing stasis and preparation method thereof | |
| CN105126034A (en) | Pharmaceutical preparation for treating coronary heart disease | |
| CN1204908C (en) | Deafness and tinnitus treating Chinese medicine and its prepn | |
| CN105106786B (en) | The external medicine composition and its preparation and preparation method of a kind of Tongluo Shujin | |
| CN103316226B (en) | Traditional Chinese medicine composition for treating coronary heart disease | |
| CN105194088A (en) | Traditional Chinese medicine preparation for treating cerebral apoplexy | |
| CN102114211A (en) | Chinese herbal medicine for treating hepatopathy |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20160203 |